microRNA-132
Cross-source consensus on microRNA-132 from 1 sources and 7 claims.
1 sources · 7 claims
Uses
How it works
Evidence quality
Highlighted claims
- Human cardiac tissue miR-132 concentrations were not measured in the trial. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- The trial rationale was based on miR-132 being upregulated after myocardial stress and regulating pathological cardiac remodeling. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- Plasma miR-132 was used as a pharmacodynamic marker in the trial. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- miR-132 has been linked to cardiomyocyte hypertrophy, impaired calcium handling, impaired contractility, myocardial fibrosis, and reduced autophagy regulation. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- Circulating miR-132 may not directly represent myocardial tissue miR-132 levels. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- Preclinical inhibition of miR-132 halted or partly reversed pathological remodeling in heart failure models. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- Plasma miR-132 partly rebounded after treatment stopped, especially in the lower-dose group. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial